Geographic atrophy is an advanced form of age-related macular degeneration (AMD) that slowly destroys the central part of the retina, leading to progressive, permanent vision loss. It affects roughly 1 million people in the United States, with about 160,000 new cases each year, and accounts for 5 to 8 million cases of AMD worldwide. Until 2023, there was no treatment at all. Now two FDA-approved drugs can slow its progression, though neither can reverse damage already done.
What Happens Inside the Eye
Your retina has a thin layer of support cells called the retinal pigment epithelium (RPE) that sits beneath the light-sensing photoreceptor cells. The RPE feeds and maintains those photoreceptors, clears cellular waste, and keeps the tiny blood vessels underneath healthy. In geographic atrophy, this support layer dies off in patches, and the photoreceptors above it die along with it.
The process starts years earlier with the buildup of drusen, small yellow deposits of lipids and cellular debris that accumulate between the RPE and the membrane it sits on. This is the earlier stage of AMD. Over time, those deposits trigger chronic inflammation, particularly through overactivation of the complement system, a part of the immune system designed to clear damaged cells. When the complement system stays switched on too long, it causes excess inflammation and begins destroying the very retinal cells it was meant to protect. The result is sharply defined patches of dead tissue that, under imaging, look like boundaries on a map. That resemblance is where the name “geographic” comes from.
How Vision Loss Feels
Geographic atrophy typically causes a growing blind spot (scotoma) near or at the center of your vision. Early on, you might notice difficulty reading in dim light or a sense that colors look washed out. As the atrophic patches expand and merge, the blind spot enlarges. Reading speed drops, and recognizing faces or fine details becomes harder.
The damage is not limited to the dead patches themselves. Retinal sensitivity also declines in the tissue just outside the lesion edges, so vision doesn’t abruptly go from normal to blind at the border. Instead there’s a gradient: the closer to the lesion, the worse the remaining vision performs. Over time, the ability to hold a steady gaze (fixation stability) deteriorates as well, making tasks like reading even more frustrating.
On average, lesions grow at a rate of about 1.66 square millimeters per year, though individual rates vary widely, from roughly 0.5 to 2.6 square millimeters per year. That variability means some people lose central vision over a few years while others progress much more slowly.
How It Differs From Wet AMD
AMD has two advanced forms: geographic atrophy (the “dry” form) and neovascular or “wet” AMD. In wet AMD, abnormal blood vessels grow beneath the retina and leak fluid or blood, causing sudden, dramatic vision loss. Geographic atrophy works differently. There are no leaking vessels. Instead, the retinal tissue gradually wastes away.
The pattern of quality-of-life decline reflects this difference. Research comparing the two forms found that people who eventually develop geographic atrophy actually experience a steadier, more gradual decline in vision-related quality of life, both before and after reaching the advanced stage. Those who develop wet AMD tend to have relatively stable quality of life beforehand, then a steep drop once the condition appears. In practical terms, geographic atrophy is a slow burn while wet AMD is more of a sudden event.
Risk Factors
Age is the strongest risk factor, with geographic atrophy overwhelmingly affecting people over 60. Beyond aging, genetics play a significant role. Variants in two genes in particular, complement factor H (CFH) on chromosome 1 and ARMS2 on chromosome 10, roughly double the risk of developing AMD. A variant in a third gene, HTRA1, carries a similar increase. Together with family history and cardiovascular disease, these genetic factors account for about a quarter of overall AMD risk in studies that have quantified the contribution.
Smoking intensity is the most consistently identified environmental risk factor for progressing to advanced AMD. Elevated cholesterol, higher body mass index, and hypertension share overlapping pathways with cardiovascular disease and have been linked to AMD in multiple studies, though the strength of those associations varies across populations.
How It Is Diagnosed
Eye doctors can spot geographic atrophy during a standard dilated eye exam, but precise measurement of the lesions relies on specialized imaging. Color fundus photography, essentially a high-resolution photograph of the back of the eye, has been the traditional method used in large studies. A more sensitive technique called fundus autofluorescence (FAF) captures the natural fluorescence of the RPE layer, making dead patches appear as dark, sharply defined areas. FAF is now considered the best available tool for defining and measuring RPE loss.
Optical coherence tomography (OCT), which creates cross-sectional scans of the retina layer by layer, adds depth information that photography alone cannot provide. Combining FAF with OCT gives clinicians both a map of the lesion’s surface area and a view of which retinal layers are thinning or already gone. This paired approach has become the preferred standard for diagnosing and monitoring geographic atrophy over time.
FDA-Approved Treatments
In February 2023, pegcetacoplan (Syfovre) became the first drug ever approved for geographic atrophy. In August 2023, avacincaptad pegol (Izervay) followed. Both are complement inhibitors, meaning they work by dialing down the overactive immune pathway that drives retinal cell death. Both require injections into the eye.
Pegcetacoplan is given monthly or every other month. In two large trials (OAKS and DERBY), monthly injections slowed lesion growth by 19 to 22 percent over two years compared with sham injections. The every-other-month schedule slowed growth by 16 to 18 percent. Avacincaptad pegol is given monthly. In its pivotal trial (GATHER2), it slowed lesion growth by 14 percent over 12 months.
These are meaningful reductions in progression, but they do not stop the disease entirely, and they cannot restore vision that has already been lost. The treatments work best as a way to preserve remaining sight for longer. For many patients, the decision to start treatment involves weighing the burden of frequent eye injections against the incremental slowing of vision loss.
Living With Geographic Atrophy
Because the disease cannot yet be reversed, low vision rehabilitation plays a central role in maintaining independence and quality of life. For close-up tasks like reading, high-powered magnifying glasses (hyperocular lenses) are the most commonly prescribed aid, recommended to nearly all patients entering rehabilitation programs. Handheld or stand magnifiers, electronic magnification devices, and specialized reading telescopes may be added depending on the severity of vision loss.
For distance vision, telescopic glasses, either Galilean or Keplerian designs, help with tasks like watching television or reading signs. Nearly half of patients in one rehabilitation study also benefited from tinted filter lenses that block specific wavelengths of light, reducing glare and improving contrast both indoors and outdoors. These filters do not change the underlying disease but can make everyday environments more visually comfortable.
Tablet and smartphone accessibility features, such as screen magnification, high-contrast display modes, and text-to-speech, serve as practical daily tools that supplement formal low vision devices. Many people with geographic atrophy find that a combination of optical aids and digital adaptations allows them to continue reading, cooking, and navigating their homes with greater confidence than they expected after diagnosis.